Trial NCT03251417

View at ClinicalTrials.gov 
Org. Study IDs: AHEAD-HBE002

Last trial update was posted on 2023-02-01

MeSH Interventions

Apatinib Irinotecan

MeSH Conditions

Carcinoma Carcinoma, Squamous Cell Esophageal Squamous Cell Carcinoma

Other Conditions


Stopping Reasons

Because PD-1 antibodies had been proved to be a standard second-line treatment in esophageal cancer, the potential benefit of present intervention is under re-evaluation.

Limitations And Caveats

N/A

Result Publications

N/A

Annotations

Category Annotations
No annotators decided on categories yet

Intervention Annotations
# Outdated Intervention Condition
Name Route DrugBank ID